Trial Profile
A Phase IIa Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Antiviral Agents/hzVSF-v13 Combination Therapy vs Oral Antiviral Monotherapy in Chronic Hepatitis B Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Burfiralimab (Primary) ; Entecavir; Tenofovir
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors ImmuneMed
- 12 Jun 2023 Planned number of patients changed from 24 to 32.
- 12 Jun 2023 Planned End Date changed from 30 Sep 2023 to 4 Dec 2024.
- 12 Jun 2023 Planned primary completion date changed from 30 Jun 2023 to 27 Mar 2024.